Aisling Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Aisling Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-67,645	Closed	-$829K	–	17
2023 Q3	$829K	Sell	67,645 -1	-0%	-$13	0.34%	15
2023 Q2	$762K	Hold	67,646	–	–	0.37%	14
2023 Q1	$490K	Hold	67,646	–	–	0.24%	13
2022 Q4	$761K	Hold	67,646	–	–	0.5%	13
2022 Q3	$890K	Hold	67,646	–	–	0.59%	14
2022 Q2	$854K	Hold	67,646	–	–	0.61%	16
2022 Q1	$3.89M	Hold	67,646	–	–	2.1%	11
2021 Q4	$8.03M	Hold	67,646	–	–	2.83%	10
2021 Q3	$13.4M	Hold	67,646	–	–	2.68%	7
2021 Q2	$11.8M	Hold	67,646	–	–	1.88%	9
2021 Q1	$13.4M	Hold	67,646	–	–	2.41%	7
2020 Q4	$13.3M	Hold	67,646	–	–	2.29%	7
2020 Q3	$12M	Hold	67,646	–	–	3.83%	6
2020 Q2	$15.6M	Buy	67,646 +16,000	+31%	+$3.05M	5.97%	4
2020 Q1	$6.02M	Hold	51,646	–	–	2.62%	6
2019 Q4	$9.86M	Hold	51,646	–	–	3.78%	4
2019 Q3	$9.93M	Hold	51,646	–	–	5.18%	6
2019 Q2	$8.84M	Buy	51,646 +2,810	+6%	+$486K	3.78%	7
2019 Q1	$9.83M	Buy	48,836 +14,091	+41%	+$2.94M	7.49%	6
2018 Q4	$6.51M	Buy	+34,745	New	+$7.37M	6.85%	6

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Aisling Capital Management's SYRE Position: Q4 2023 in Review

Aisling Capital Management sold out of Spyre Therapeutics (SYRE) in Q4 2023, closing a stake of 67,645 shares — an estimated $829K sold.

Aisling Capital Management first reported a position in SYRE in Q4 2018 and held it in 20 quarters. The position peaked at $15.6M in Q2 2020. 54 funds tracked by Wall St. Rank hold SYRE as of Q4 2023.

Aisling Capital Management reported no remaining Spyre Therapeutics position as of Q4 2023 after selling out during the quarter.
Aisling Capital Management sold 67,645 Spyre Therapeutics shares in Q4 2023, an estimated $829K.
Aisling Capital Management first reported a position in Spyre Therapeutics in Q4 2018 and held it in 20 quarters.
Aisling Capital Management's Spyre Therapeutics position peaked at $15.6M in Q2 2020.
54 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2023.

Based on Aisling Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.